David R. Rahn & Associates Inc. raised its holdings in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) by 11.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,624 shares of the exchange traded fund’s stock after acquiring an additional 2,109 shares during the quarter. SPDR S&P Biotech ETF makes up 2.0% of David R. Rahn & Associates Inc.’s investment portfolio, making the stock its 18th largest holding. David R. Rahn & Associates Inc.’s holdings in SPDR S&P Biotech ETF were worth $1,963,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the business. Mycio Wealth Partners LLC bought a new stake in shares of SPDR S&P Biotech ETF in the 2nd quarter valued at approximately $249,000. Reilly Financial Advisors LLC grew its stake in shares of SPDR S&P Biotech ETF by 21.2% in the 2nd quarter. Reilly Financial Advisors LLC now owns 152,508 shares of the exchange traded fund’s stock valued at $14,517,000 after buying an additional 26,641 shares in the last quarter. Daniel Devine & Co grew its stake in shares of SPDR S&P Biotech ETF by 17.5% in the 2nd quarter. Daniel Devine & Co now owns 7,400 shares of the exchange traded fund’s stock valued at $704,000 after buying an additional 1,100 shares in the last quarter. Swarthmore Group Inc. bought a new stake in shares of SPDR S&P Biotech ETF in the 2nd quarter valued at approximately $6,168,000. Finally, Patten & Patten Inc. TN grew its stake in shares of SPDR S&P Biotech ETF by 21.1% in the 2nd quarter. Patten & Patten Inc. TN now owns 8,545 shares of the exchange traded fund’s stock valued at $813,000 after buying an additional 1,490 shares in the last quarter.

Shares of SPDR S&P Biotech ETF traded up $0.20, hitting $100.33, during trading hours on Thursday, according to MarketBeat. The stock had a trading volume of 247,385 shares, compared to its average volume of 4,722,290. SPDR S&P Biotech ETF has a 52 week low of $74.25 and a 52 week high of $101.55.

The company also recently declared a quarterly dividend, which was paid on Wednesday, June 20th. Investors of record on Monday, June 18th were paid a $0.0585 dividend. The ex-dividend date of this dividend was Friday, June 15th. This represents a $0.23 annualized dividend and a dividend yield of 0.23%.

SPDR S&P Biotech ETF Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Featured Article: Book Value Of Equity Per Share – BVPS Explained

Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI).

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.